Johnson & Johnson stock at EUR 250.58, down 0.60% premarket
Published on 11/11/2026 at 08:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Johnson & Johnson develops medicines, medical devices and consumer health products.
- The premarket indication points to a weaker start after the latest Xetra session.
- Pipeline progress and regulatory milestones remain important drivers for the diversified healthcare group.
Johnson & Johnson stock traded at EUR 250.58 on Lang & Schwarz at 08:06 CET on Wednesday, November 11, 2026, 0.60 percent below the Xetra close of Tuesday, November 10, at EUR 252.10.
The premarket signal puts the healthcare group on course for a weaker opening in Europe. Johnson & Johnson combines pharmaceutical activities with medical devices and consumer health products, giving investors exposure to several healthcare markets rather than a single therapeutic area.
Pipeline progress remains central
For the share, investors continue to focus on clinical development, regulatory decisions and commercial execution across the group. The diversified portfolio can help balance individual product risks, but research outcomes and approval timelines remain important catalysts for the pharmaceutical business.
In the broader U.S. market, investors will also watch the S&P 500.
